March 17, 2023 07:32 AM EDTUpdated 08:27 AM

Moderna's 'surprise' IP court order could set up a big settlement for Roivant, Arbutus — analysts

Zachary Brennan

Senior Editor

The battle over who owns the patented lipid nanoparticle technology that carried the Covid-19 vaccines across the finish line and into millions of people’s arms …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Moderna's 'surprise' IP court order could set up a big settlement for Roivant, Arbutus — analysts

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

Mod­er­na's 'sur­prise' IP court or­der could set up a big set­tle­ment for Roivant, Ar­bu­tus — an­a­lysts

Senior Editor

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Moderna's 'surprise' IP court order could set up a big settlement for Roivant, Arbutus — analysts